$BNTC

Citizens reiterated a Market Outperform rating and $24.00 price target for Benitec Biopharma (NASDAQ: BNTC), citing constructive FDA feedback on its BB-301 study. The target suggests significant upside from the current $9.23 share price. Benitec plans to finalize the study design with the FDA in Q1 2027 and present updated data at ESGCT. Analysts maintain a Strong Buy consensus, with targets ranging from $17 to $32. The company also appointed Ernst & Young as its new auditor.

Benitec Biopharma Inc.'s average stock price target increased to $24.33 from $23.2, with estimates ranging from $17 to $32. This implies a 171% upside from the Oct. 2 closing price. All 7 analysts rate the stock as 'Buy'.

Benitec Biopharma (BNTC) reported that its BB-301 pivotal trial remains on track to start mid-2027, following FDA Type C meeting feedback. The FDA requested additional data, including from Benitec's OPMD Natural History Study, to inform the trial's design. The FDA agreed to review submitted data, allowing final pivotal study design confirmation in 1Q 2027. Benitec plans to present 12-month Cohort 1 and interim Cohort 2 BB-301 Phase 1b/2a data at ESGCT in October 2026.

Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Regulation FD Disclosure. Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study • The BB-301 pivotal trial remains on track to begin in mid-2027 • Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these di

Benitec Biopharma reported FY 2026 revenue of $0 and a net loss of $45.5 million, with cash doubling to $180 million. Shares fell 8.53% post-announcement. The company is in clinical trials for BB-301, targeting OPMD-related dysphagia, with pivotal study plans expected in October 2026 and initiation in mid-2027.

Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all thre

-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...

HAYWARD, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...

BB-301 has also been granted Orphan Drug Designation from both FDA and EMA Following the administration of BB-301, Cohort 1 patients experienced significant continuing reductions in dysphagic symptom burden, post-swallow residue accumulation, time required to consume fixed volumes of liquid, and ...

HAYWARD, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ( ...